FDA Cleared

DermaSensor
request a demo
Request a Demo
Order Now

50% Off for the First 3 Months – Now $199/Month (Regularly $399 for Unlimited Users & Patients). Now Shipping!

Health Systems

An AI-powered platform to improve patient assessment and cancer diagnosis across your patient population.

Request A Demo

If you’re interested in exploring a partnership with us, please click here to get in touch with a member of our executive team directly.

The Challenge

Skin cancer is a pervasive and underdiagnosed health concern in the United States, exacerbated by the inefficiencies within the healthcare system, resulting in preventable morbidity.  Physicians, who are on the frontline to appropriately treat and triage a host of conditions, have had a lack of adequate diagnostic aids to assess skin lesions. There is an unmet need for tools to improve the identification of lesions requiring referral, which may otherwise lead to delayed or missed detection of skin cancer.

The Solution

Powered by FDA-Breakthrough technology, DermaSensor delivers accurate results at the fingertips of healthcare providers. 

Designed with efficiency in mind, DermaSensor ensures rapid, objective test results without compromising quality. Its user-friendly interface makes it effortlessly accessible and easy to incorporate into the busy routine of medical offices. This powerful tool enhances and streamlines physicians’ management process for suspicious skin lesions and translates to tangible value for healthcare systems.

DermaSensor’s capabilities pave the way for more informed decision-making, since the device was found to have a 96% device sensitivity for correctly referring skin cancer in a study of 1,579 lesions and 224 skin cancers. Its rapid results can help minimize healthcare provider and patient time associated with referrals, creating a ripple effect of benefits for the healthcare ecosystem. Ultimately, DermaSensor improves PCPs cancer detection and appropriate referrals to dermatology, marking a significant advancement in skin cancer care in the U.S.

Request A Demo

Empowering Clinicians with Enhanced Precision

DermaSensor is a real-time, non-invasive skin cancer evaluation system that provides point-of-care testing for all types of skin cancer.

The Burden of Skin Cancer

In the U.S., more than 9,500 people are diagnosed with skin cancer every day. More than two people die of the disease every hour and at least one in five Americans will develop skin cancer by the age of 70.*

Source: https://www.skincancer.org/skin-cancer-information/skin-cancer-facts/

While skin cancer is highly treatable at early stages, delays in identification substantially increased risk. Effective assessment of patients with potential skin cancer in primary care settings can be challenging due to handling diverse and increasing medical concerns and having limited dermatological training. But now, physicians can use DermaSensor’s AI-powered spectroscopy technology to non-invasively evaluate cellular and subcellular characteristics of a lesion in question for skin cancer. The wireless, handheld device then provides an immediate, objective result using the FDA-cleared algorithm.

off your first 3 months
year end special
0 %
Request a Demo Now

Applies to $399 monthly rental rate only (unlimited users and patients)

Select Your Monthly Rental Plan After the 3-Month Promo

$199/month(Up to 5 patients)

OR

$399/month(Unlimited Users & Scans)

Watch Product Demo
Request A Demo

Discover what other practitioners are saying.

Our study indicates that DermaSensor’s ESS device has the potential to enhance the detection of skin malignancies in the primary care setting. This technology not only improved PCPs’ sensitivity for lesion referral but also significantly increased their confidence, both of which are particularly important for non-specialists
Laura Korb Ferris, MD
Laura Korb Ferris, MDProfessor of Dermatology and Director of the University of Pittsburgh
Department of Dermatology Clinical Trials Unit
The dermatology community and I have been advocating the use of dermatoscopes for decades with primary care physicians, but with limited success given the significant and repeated training that is needed. I'm thrilled that this new automated device is now available for these physicians with training time of just a few minutes.
Dr. Harold Rabinovitz, MDBoard Certified Dermatologist, Professor of Dermatology, Medical College of Georgia
As skin cancer rates continue to rise, the need for accurate and efficient skin cancer detection in primary care is increasingly important. These studies have shown the ESS device benefits physicians, and it is also a non-invasive, easy-to-use solution for instantaneously evaluating suspicious lesions.
Dr. Daniel Siegel
Dr. Daniel SiegelClinical Professor of Dermatology at SUNY Downstate and the principal investigator
for the DERM-SUCCESS clinical utility study
In primary care, we don't want to miss a chance to catch skin cancer as soon as possible, but skin lesions can be challenging to evaluate. DermaSensor is fast and easy to use and adds objectivity and confidence to these clinical decisions.
Todd Thames MD MHABoard Certified Family Medicine Physician, Instructor, Trinity University
As a dermatologist that trained PCPs at One Medical for years, I think this device will be transformational for PCPs correctly managing suspicious lesions.
Holly Christman MD
Holly Christman MDBoard Certified Dermatologist and Mohs surgeon, Assistant Clinical Professor of Dermatology,
University of California, San Francisco
The DermaSensor device will be a great service to provide to my patients who are concerned about skin lesions, and an invaluable tool to help me decide how to manage their care."
Dr. Dean Hildahl
Dr. Dean Hildahl North Naples Gynecology and Obstetrics
In sunny Miami, skin cancer is a real concern. I'm excited to use a new non-invasive, FDA-cleared, AI-powered device to improve detection accuracy and provide peace of mind for high-risk patients
Dr. Eduardo Alarcon
Dr. Eduardo AlarconRegen and Anti Aging Med at IRTMedical
As a PCP I can incorporate this FDA cleared device on patients during their skin assessment. But where I really see a tremendous value for this tool is during our massages and facials. Our team is trained to identify suspicious lesions and having DermaSensor gives us greater confidence in be able to help our clients
Dr. Alexander Zuriarrain
Dr. Alexander ZuriarrainHydrology Wellness
Google said it was cancer but let’s assess your lesion now with our new age AI assisted skin cancer screening device to provide real time objective results
Dr. Patrick Sciara
Dr. Patrick SciaraAlliance Medical Clinic
" I am super excited to announce that we have a new device called DermaSensor at Montgomery Medical. I originally had the opportunity to work with DermaSensor through a clinical trial at Frontier Clinical Research. Now that it is FDA-cleared, we are excited to be one of the first PCP offices to offer this new technology that uses light to help us assess suspicious skin lesions. It is painless and only takes a few seconds to give us an immediate result
Dr. Marcy J. Goisse
Dr. Marcy J. GoisseMontgomery Medical
At Sanctum Med + Wellness, we deliver exceptional healthcare services prioritizing patient well-being and addressing every aspect of their health. Adding the DermaSensor device to our comprehensive range of services further underscores our commitment to staying at the forefront of medical innovation
Dr. Jessica Shepherd
Dr. Jessica ShepherdSANCTUM MED + WELLNESS
We are proud to be the first medical practice in the northern half of the United States to offer this innovative solution, and we are confident it will make a profound impact on our approach to skin health
Dr. Brian Hollett, MD
Dr. Brian Hollett, MDSHIFT | Concierge Primary Care in Chicago

Featured In

TIME Best Inventions of 2024 Medical Care Category

Contact Us

80-0009.2 v2

Health Systems

Health Systems